JP6495908B2 - ピリジノン - Google Patents
ピリジノン Download PDFInfo
- Publication number
- JP6495908B2 JP6495908B2 JP2016533909A JP2016533909A JP6495908B2 JP 6495908 B2 JP6495908 B2 JP 6495908B2 JP 2016533909 A JP2016533909 A JP 2016533909A JP 2016533909 A JP2016533909 A JP 2016533909A JP 6495908 B2 JP6495908 B2 JP 6495908B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- mmol
- substituted
- compound according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC([C@@]1N(*)c2cc(*)c(*)cc2N1)=I*N(*)C(C(*)=C)=O Chemical compound CC([C@@]1N(*)c2cc(*)c(*)cc2N1)=I*N(*)C(C(*)=C)=O 0.000 description 15
- ZSIUXTUVHIYRKJ-UHFFFAOYSA-N CC(C1)C(N)=NNC1=O Chemical compound CC(C1)C(N)=NNC1=O ZSIUXTUVHIYRKJ-UHFFFAOYSA-N 0.000 description 2
- WSSJEINFFUTORW-UHFFFAOYSA-N CC(C1)C(c(cc2)cc(N)c2NCc2ccccc2)=NNC1=O Chemical compound CC(C1)C(c(cc2)cc(N)c2NCc2ccccc2)=NNC1=O WSSJEINFFUTORW-UHFFFAOYSA-N 0.000 description 1
- JPKADUBXIMIGGU-UHFFFAOYSA-N CC(c(cc1NCc2ccccn2)ncc1[N+]([O-])=O)=C Chemical compound CC(c(cc1NCc2ccccn2)ncc1[N+]([O-])=O)=C JPKADUBXIMIGGU-UHFFFAOYSA-N 0.000 description 1
- AWNBPGRFIZUPKD-UHFFFAOYSA-N CC(c1ncccc1)[n]1c(C(C=C2C)=CN(C)C2=O)nc(cn2)c1cc2OCC1CC1 Chemical compound CC(c1ncccc1)[n]1c(C(C=C2C)=CN(C)C2=O)nc(cn2)c1cc2OCC1CC1 AWNBPGRFIZUPKD-UHFFFAOYSA-N 0.000 description 1
- UBHABGPIPKAICI-UHFFFAOYSA-N CC1=CC(c([n](Cc2ccccc2)c2c3)nc2ccc3N)=CN(C)C1=O Chemical compound CC1=CC(c([n](Cc2ccccc2)c2c3)nc2ccc3N)=CN(C)C1=O UBHABGPIPKAICI-UHFFFAOYSA-N 0.000 description 1
- RGZCKPXTNJAWMR-UHFFFAOYSA-N CN(C=C(C=C1)C(O)=O)C1=O Chemical compound CN(C=C(C=C1)C(O)=O)C1=O RGZCKPXTNJAWMR-UHFFFAOYSA-N 0.000 description 1
- ITRUWWKXJNZPFX-UHFFFAOYSA-N CN(CC1)CCN1c(cc1)nc(NCc2ccccc2)c1N Chemical compound CN(CC1)CCN1c(cc1)nc(NCc2ccccc2)c1N ITRUWWKXJNZPFX-UHFFFAOYSA-N 0.000 description 1
- KQBMBZGNIPGFCG-UHFFFAOYSA-N CN(CC1)CCN1c1ccc2nc(C(C=C3)=CN(C)C3=O)[n](Cc3ccccc3)c2n1 Chemical compound CN(CC1)CCN1c1ccc2nc(C(C=C3)=CN(C)C3=O)[n](Cc3ccccc3)c2n1 KQBMBZGNIPGFCG-UHFFFAOYSA-N 0.000 description 1
- OYGPOBCNKHZOPZ-UHFFFAOYSA-N Nc(c(NCc1ccccc1)c1)cnc1N1CCOCC1 Chemical compound Nc(c(NCc1ccccc1)c1)cnc1N1CCOCC1 OYGPOBCNKHZOPZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13180404.9 | 2013-08-14 | ||
| EP13180404 | 2013-08-14 | ||
| PCT/EP2014/067263 WO2015022332A1 (en) | 2013-08-14 | 2014-08-12 | Pyridinones |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016530259A JP2016530259A (ja) | 2016-09-29 |
| JP2016530259A5 JP2016530259A5 (enExample) | 2017-09-21 |
| JP6495908B2 true JP6495908B2 (ja) | 2019-04-03 |
Family
ID=48951412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533909A Active JP6495908B2 (ja) | 2013-08-14 | 2014-08-12 | ピリジノン |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20150051208A1 (enExample) |
| EP (1) | EP3033335B1 (enExample) |
| JP (1) | JP6495908B2 (enExample) |
| WO (1) | WO2015022332A1 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9266891B2 (en) | 2012-11-16 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors |
| WO2014096965A2 (en) | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2015004533A2 (en) | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| SG11201510409QA (en) | 2013-06-21 | 2016-01-28 | Zenith Epigenetics Corp | Novel bicyclic bromodomain inhibitors |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2015015318A2 (en) | 2013-07-31 | 2015-02-05 | Zenith Epigenetics Corp. | Novel quinazolinones as bromodomain inhibitors |
| AU2014337064B2 (en) | 2013-10-18 | 2019-03-14 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
| EP3074389B1 (en) * | 2013-11-26 | 2019-08-14 | Gilead Sciences, Inc. | Quinoline derivatives as bromodomain inhibitors |
| GB201321737D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| US9920052B2 (en) * | 2013-12-09 | 2018-03-20 | Ucb Biopharma Sprl | Imidazopyridine derivatives as modulators of TNF activity |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| EP3227280B1 (en) | 2014-12-01 | 2019-04-24 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| JP2017537946A (ja) | 2014-12-11 | 2017-12-21 | ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． | ブロモドメイン阻害剤としての置換複素環 |
| HK1245247A1 (zh) | 2014-12-17 | 2018-08-24 | 恒翼生物医药科技(上海)有限公司 | 溴结构域的抑制剂 |
| GB201503720D0 (en) * | 2015-03-05 | 2015-04-22 | Glaxosmithkline Ip No 2 Ltd | Chemical compound |
| AU2016232705C1 (en) | 2015-03-18 | 2021-06-17 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
| GB201504689D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| GB201506660D0 (en) * | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| JP2018526430A (ja) | 2015-07-10 | 2018-09-13 | アルヴィナス・インコーポレイテッド | タンパク質分解のｍｄｍ２系修飾因子および関連の使用方法 |
| CA2994969A1 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| JP2018527340A (ja) | 2015-08-11 | 2018-09-20 | ネオメド インスティテュートＮｅｏｍｅｄ Ｉｎｓｔｉｔｕｔｅ | アリール置換ジヒドロキノリノン、その調製及び医薬品としてのその使用 |
| US10836742B2 (en) | 2015-08-11 | 2020-11-17 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
| CA2994478C (en) | 2015-08-12 | 2023-10-03 | Neomed Institute | Substituted benzimidazoles, their preparation and their use as pharmaceuticals |
| WO2017030814A1 (en) | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| US10501459B2 (en) | 2015-10-21 | 2019-12-10 | Neomed Institute | Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors |
| CN108602821B (zh) * | 2015-12-14 | 2021-06-29 | 恒元生物医药科技(苏州)有限公司 | 1h-咪唑并[4,5-b]吡啶基bet溴结构域抑制剂 |
| WO2017127930A1 (en) * | 2016-01-28 | 2017-08-03 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals |
| WO2017172914A1 (en) | 2016-03-30 | 2017-10-05 | Wisconsin Alumni Research Foundation | Methods and compositions for modulating frataxin expression |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| ES2989988T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros heterorocíclicos para la degradación de proteínas diana |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| GB201614940D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Intellectual Property (No 2) Ltd | Chemical compounds |
| GB201614939D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Ip Dev Ltd | Crystalline hydrate |
| WO2018106667A1 (en) | 2016-12-05 | 2018-06-14 | Microbiotix, Inc. | Broad-spectrum inhibitors of filoviruses |
| JP2020506922A (ja) | 2017-01-31 | 2020-03-05 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物 |
| EP3580212A4 (en) | 2017-02-08 | 2021-03-17 | Dana Farber Cancer Institute, Inc. | REGULATION OF CHEMERIC ANTIGEN RECEPTORS |
| WO2018183679A1 (en) | 2017-03-29 | 2018-10-04 | Wisconsin Alumni Research Foundation | Methods and compositions for modulating gene expression |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CN109111437B (zh) * | 2017-06-22 | 2022-03-04 | 中国科学院广州生物医药与健康研究院 | 一种苯并[d]异恶唑类化合物及其制备方法和应用 |
| CN109280046B (zh) * | 2017-07-21 | 2021-02-02 | 浙江海正药业股份有限公司 | 苯并咪唑类衍生物及其制备方法及其在医药上的用途 |
| CN110997656B (zh) * | 2017-08-04 | 2023-04-14 | 百时美施贵宝公司 | 用作tlr7/8/9抑制剂的取代的吲哚化合物 |
| US20210038602A1 (en) * | 2018-01-25 | 2021-02-11 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia |
| WO2019148055A1 (en) | 2018-01-26 | 2019-08-01 | Yale University | Imide-based modulators of proteolysis and methods of use |
| US10442799B1 (en) | 2018-04-07 | 2019-10-15 | Fuqiang Ruan | Heterocyclic compounds and uses thereof |
| CN112262134B (zh) | 2018-04-13 | 2024-05-24 | 阿尔维纳斯运营股份有限公司 | 小脑蛋白配体和包括其的双官能化合物 |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| JP2022053557A (ja) * | 2019-02-08 | 2022-04-06 | マルホ株式会社 | ピリドン誘導体 |
| US12497395B2 (en) * | 2019-04-24 | 2025-12-16 | Convergene, Llc | Small molecule bromodomain inhibitors and uses therof |
| WO2021065980A1 (ja) | 2019-09-30 | 2021-04-08 | 協和キリン株式会社 | Ｂｅｔ分解剤 |
| PE20221582A1 (es) | 2019-12-19 | 2022-10-06 | Arvinas Operations Inc | Compuestos y metodos para la degradacion dirigida de receptor de androgenos |
| WO2021175432A1 (en) | 2020-03-04 | 2021-09-10 | Boehringer Ingelheim International Gmbh | Method for administration of an anti cancer agent |
| WO2024050016A1 (en) | 2022-08-31 | 2024-03-07 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
| WO2025049555A1 (en) | 2023-08-31 | 2025-03-06 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004010207A1 (de) * | 2004-03-02 | 2005-09-15 | Aventis Pharma S.A. | Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate |
| CN101454325A (zh) * | 2006-03-09 | 2009-06-10 | 法马科皮亚公司 | 用于治疗代谢性疾病的8-杂芳基嘌呤mnk2抑制剂 |
| AR063141A1 (es) * | 2006-10-04 | 2008-12-30 | Pharmacopeia Inc | Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion |
| US8975247B2 (en) * | 2009-03-18 | 2015-03-10 | The Board Of Trustees Of The Leland Stanford Junion University | Methods and compositions of treating a flaviviridae family viral infection |
| EP2439197A1 (en) * | 2010-10-07 | 2012-04-11 | Santhera Pharmaceuticals (Schweiz) AG | Substituted benzimidazole derivatives as melanocortin 4 receptor antagonists |
-
2014
- 2014-08-11 US US14/456,038 patent/US20150051208A1/en not_active Abandoned
- 2014-08-12 JP JP2016533909A patent/JP6495908B2/ja active Active
- 2014-08-12 EP EP14750485.6A patent/EP3033335B1/en active Active
- 2014-08-12 WO PCT/EP2014/067263 patent/WO2015022332A1/en not_active Ceased
-
2015
- 2015-05-18 US US14/714,521 patent/US9296748B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3033335A1 (en) | 2016-06-22 |
| US20150246919A1 (en) | 2015-09-03 |
| US20150051208A1 (en) | 2015-02-19 |
| US9296748B2 (en) | 2016-03-29 |
| EP3033335B1 (en) | 2020-04-15 |
| JP2016530259A (ja) | 2016-09-29 |
| WO2015022332A1 (en) | 2015-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6495908B2 (ja) | ピリジノン | |
| JP6370368B2 (ja) | Ｂｒｄ４阻害剤としてのインドリノン類似体 | |
| JP6370376B2 (ja) | Ｂｒｄ４阻害薬としてのトリアゾロピラジン誘導体 | |
| US9199988B2 (en) | Dihydroquinazolinone analogues | |
| AU2013346809B2 (en) | Triazolopyrazine | |
| JP6085873B2 (ja) | トリアゾロピリダジン | |
| JP6488367B2 (ja) | ベンゾイミダゾール誘導体 | |
| EP2571877A1 (en) | 1h - imidazo [4, 5 - c]quinolines | |
| US10413536B2 (en) | 6-alkyny-pyridine derivatives | |
| WO2015025018A1 (en) | New bis-amido pyridines | |
| US8466162B2 (en) | 5-alkynyl-pyridines | |
| US8598157B2 (en) | 5-alkynyl-pyridines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170814 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170814 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180621 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180702 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181002 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190207 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190307 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6495908 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |